Altered role of smooth muscle endothelin receptors in coronary endothelin-1 and α1-adrenoceptor-mediated vasoconstriction in Type 2 diabetes

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 4, 2007, Pages

  Bender, S B ^a,b   Klabunde, R E ^a  

^a OHIO UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

C57BL 6J mouse; Diet induced diabetes; Isolated heart

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N(G) NITROARGININE METHYL ESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; C57BL 6 MOUSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ISOLATED HEART; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; VASOCONSTRICTION;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIETARY CARBOHYDRATES; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENZYME INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OBESITY; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PHENYLEPHRINE; PIPERIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ADRENERGIC, ALPHA-1; VASOCONSTRICTION;

EID: 35349002741     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00566.2007     Document Type: Article

References (47)

1. Bender SB, Herrick EK, Lott ND, Klabunde RE. Diet-induced obesity and diabetes reduces coronary responses to nitric oxide due to reduced bioavailability in isolated mouse hearts. Diabetes, Obesity, and Metabolism 9: 688-696, 2007.
2. B receptors induces BQ-123-sensitive hypertension in the mouse. Hypertension 36: 1002-1007, 2000.
3. Berthiaume N, Yanagisawa M, Yanagisawa H, deWit D, D'Orleans-Juste P. Pharmacology of endothelins in vascular circuits of normal or heterozygous endothelin-A or endothelin-B knockout transgenic mice. J Cardiovasc Pharmacol 31, Suppl 1: S561-S564, 1998.
4. Bohm F, Ahlborg G, Johansson BL, Hansson LO, Pernow J. Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis. Arterioscler Thromb Vasc Biol 22: 674-679, 2002.
5. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest 85: 587-590, 1990.
6. D'Angelo G, Pollock JS, Pollock DM. Endogenous endothelin attenuates the pressor response to acute environmental stress via the ETA receptor. Am J Physiol Heart Circ Physiol 288: H1829-H1835, 2005.
7. 1-adrenergic stimulation. Am J Physiol Heart Circ Physiol 290: H1251-H1258, 2006.
8. Filep JG, Battistini B, Cote YP, Beaudoin AR, Sirois P. Endothelin-1 induces prostacyclin release from bovine aortic endothelial cells. Biochem Biophys Res Commun 177: 171-176, 1991.
9. Garcia-Sainz JA, Vazquez-Cuevas FG, Romero-Avila M. T phosphorylation and desensitization of alpha1d-adrenergic receptors. Biochem J 353: 603-610, 2001.
10. Garcia-Villalon AL, Monge L, Fernandez N, Sanchez MA, Martinez MA, Gomez B, Dieguez G. Basal inhibitory action of endogenous endothelin on the sympathetic contraction in the isolated rat tail artery. Eur J Pharmacol 384: 163-167, 1999.
11. Goligorsky MS, Tsukahara H, Magazine H, Andersen TT, Malik AB, Bahou WF. Termination of endothelin signaling: role of nitric oxide. J Cell Physiol 158: 485-494, 1994.
12. B receptor heterodimer. Cell Mol Neurobiol 22: 207-226, 2002.
13. B receptors differentially modulate afferent and efferent arteriolar responses to endothelin. Br J Pharmacol 146: 1019-1026, 2005.
14. Iwasa S, Fan J, Shimokama T, Nagata M, Watanabe T. Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis. Atherosclerosis 146: 93-100, 1999.
15. Juan CC, Fang VS, Hsu YP, Huang YJ, Hsia DB, Yu PC, Kwok CF, Ho LT. Overexpression of vascular endothelin-1 and endothelin-A receptors in a fructose-induced hypertensive rat model. J Hypertens 16: 1775-1782, 1998.
16. A receptors. Am J Physiol Renal Physiol 286: F660-F668, 2004.
17. Katakam PVG, Pollock JS, Pollock DM, Ujhelyi MR, Miller AW. Enhanced endothelin-1 response and receptor expression in small mesenteric arteries of insulin-resistant rats. Am J Physiol Heart Circ Physiol 280: H522-H527, 2001.
18. Kelly LK, Wedgwood S, Steinhorn RH, Black SM. Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase. Am J Physiol Lung Cell Mol Physiol 286: L984-L991, 2004.
19. Laguad GJ, Masih-Khan E, Kai S, van Breemen C, Dube GP. Influence of type II diabetes on arterial tone and endothelial function in murine mesenteric resistance arteries. J Vasc Res 38: 578-589, 2001.
20. Mills E, Kuhn CM, Feinglos MN, Surwit R. Hypertension in CB57BL/6J mouse model of noninsulin-dependent diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 264: R73-R78, 1993.
21. Nafrialdi N, Jover B, Mimran A. Endogenous vasoactive systems and the pressor effect of acute N omega-nitro-L-arginine methyl ester administration. J Cardiovasc Pharmacol 23: 765-771, 1994.
22. Neylon CB. Vascular biology of endothelin signal transduction. Clin Exp Pharmacol Physiol 26: 149-153, 1999.
23. Perez-Rivera AA, Fink GD, Galligan JJ. Vascular reactivity of mesenteric arteries and veins to endothelin-1 in a murine model of high blood pressure. Vascul Pharmacol 43: 1-10, 2005.
24. Perin PC, Maule S, Quadri R. Sympathetic nervous system, diabetes, and hypertension. Clin Exp Hypertens 23: 45-55, 2001.
25. Petersen HH, Choy J, Stauffer B, Moien-Afshari F, Aalkjaer C, Leinwand L, McManus BM, Laher I. Coronary artery myogenic response in a genetic model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 283: H2244-H2249, 2002.
26. Pierre LN, Davenport AP. Endothelin receptor subtypes and their functional relevance in human small coronary arteries. Br J Pharmacol 124: 499-506, 1998.
27. Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J 9: 1196-1204, 1995.
28. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nature clinical practice 3: 46-56, 2007.
29. Richard V, Hogie M, Clozel M, Loffler BM, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 91: 771-775, 1995.
30. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Piccoli A, Valentini U, Cimino A, Girelli A, Salvetti M, De Ciuceis C, Tiberio GA, Giulini SM, Sleiman I, Monteduro C, Rosei EA. Endothelial dysfunction in small resistance arteries of patients with noninsulin-dependent diabetes mellitus. J Hypertens 19: 913-919, 2001.
31. Sachidanandam K, Harris A, Hutchinson J, Ergul A. Microvascular vs. macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1. Exp Biol Med (Maywood) 231: 1016-1021, 2006.
32. Shemyakin A, Bohm F, Wagner H, Efendic S, Bavenholm P, Pernow J. Enhanced endothelium-dependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance. J Cardiovasc Pharmacol 47: 385-390, 2006.
33. Stepp DW, Merkus D, Nishikawa Y, Chilian WM. Nitric oxide limits coronary vasoconstriction by a shear stress-dependent mechanism. Am J Physiol Heart Circ Physiol 281: H796-H803, 2001.
34. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37: 1163-1167, 1988.
35. B-induced relaxation. Br J Pharmacol 146: 903-912, 2005.
36. Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 20: 2239-2245, 2002.
37. B receptor in endothelial cells. J Biol Chem 269: 21778-21785, 1994.
38. b-adrenoceptors in rat-1 fibroblasts. J Biol Chem 272: 27330-27337, 1997.
39. Verma S, Arikawa E, Lee S, Dumont AS, Yao L, McNeill JH. Exaggerated coronary reactivity to endothelin-1 in diabetes: reversal with bosentan. Can J Physiol Pharmacol 80: 980-986, 2002.
40. Verma S, Skarsgard P, Bhanot S, Yao L, Laher I, McNeill JH. Reactivity of mesenteric arteries from fructose hypertensive rats to endothelin-1. Am J Hypertens 10: 1010-1019, 1997.
41. Wang QD, Gonon A, Shimizu M, Sjoquist PO, Pernow J. Contribution of endothelin to the coronary vasoconstriction in the isolated rat heart induced by nitric oxide synthase. Acta Physiol Scand 163: 325-330, 1998.
42. Wiley KE, Davenport AP. Nitric oxide-mediated modulation of the endothelin-1 signaling pathway in the human cardiovascular system. Br J Pharmacol 132: 213-220, 2001.
43. Wu SQ, Hopfner RL, McNeill JR, Wilson TW, Gopalakrishnan V. Altered paracrine effect of endothelin in blood vessels of the hyperinsulinemic, insulin resistant obese Zucker rat. Cardiovasc Res 45: 994-1000, 2000.
44. Yang M, Ruan J, Voller M, Schalken J, Michel MC. Differential regulation of human alpha1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 359: 439-446, 1999.
45. Yoshida Y, Ohyanagi M, Iwasaki T. Chronological changes of alpha-adrenoceptor-mediated vascular constriction in Otsuka-Long-Evans-Tokushima fatty rats. Hypertens Res 26: 559-567, 2003.
46. Zellers TM, McCormick J, Wu Y. Interaction among ET-1, endothelium-derived nitric oxide, and prostacyclin in pulmonary arteries and veins. Am J Physiol Heart Circ Physiol 267: H139-H147, 1994.
47. Zhou Y, Dirksen WP, Zweier JL, Periasamy M. Endothelin-1-induced responses in isolated mouse vessels: the expression and function of receptor types. Am J Physiol Heart Circ Physiol 287: H573-H578, 2004.